Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Rudwaleit

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
RMD Open|March 17, 2022
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd studyDésirée van der Heijde, Lianne S Gensler, Walter P Maksymowych, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|March 1, 2008
From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseasesMarta Steinbrich-Zöllner, Joachim R Grün, Toralf Kaiser, et al.
Arthritis and Rheumatism|September 2, 2006
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitisHeiner Appel, Maren Kuhne, Simone Spiekermann, et al.
The Journal of Rheumatology|October 6, 2005
Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7Désirée M F M van der Heijde, Robert B M Landewé, Kay-Geert A Hermann, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW studyIrene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, et al.
The Journal of Rheumatology|July 17, 2014
Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trialIn-Ho Song, Kay-Geert Hermann, Hildrun Haibel, et al.
RMD Open|April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
Arthritis and Rheumatism|April 3, 2008
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosusRobert Biesen, Cemal Demir, Fidan Barkhudarova, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study groupKay-Geert A Hermann, Xenofon Baraliakos, Désirée M F M van der Heijde, et al.
Arthritis Research & Therapy|May 19, 2005
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabXenofon Baraliakos, Joachim Listing, Jan Brandt, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
RMD Open|March 17, 2022
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd studyDésirée van der Heijde, Lianne S Gensler, Walter P Maksymowych, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|March 1, 2008
From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseasesMarta Steinbrich-Zöllner, Joachim R Grün, Toralf Kaiser, et al.
Arthritis and Rheumatism|September 2, 2006
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitisHeiner Appel, Maren Kuhne, Simone Spiekermann, et al.
The Journal of Rheumatology|October 6, 2005
Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7Désirée M F M van der Heijde, Robert B M Landewé, Kay-Geert A Hermann, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW studyIrene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, et al.
The Journal of Rheumatology|July 17, 2014
Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trialIn-Ho Song, Kay-Geert Hermann, Hildrun Haibel, et al.
RMD Open|April 10, 2024
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, et al.
Arthritis and Rheumatism|April 3, 2008
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosusRobert Biesen, Cemal Demir, Fidan Barkhudarova, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study groupKay-Geert A Hermann, Xenofon Baraliakos, Désirée M F M van der Heijde, et al.
Arthritis Research & Therapy|May 19, 2005
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabXenofon Baraliakos, Joachim Listing, Jan Brandt, et al.
Pageof 15